The KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and thyroid cancer. The existence of KRAS mutations is often associated with a prognostic marker of drug response. For example, the KRAS mutation is considered a strong prognostic marker for drug response to tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related to drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) used for colon cancer therapy. Therefore, KRAS mutation testing is necessary to determine drug resistance in patients with colorectal or lung cancer and will be useful for anticancer therapies.
PANAMutyper™ R KRAS
To detect KRAS mutations and determine their response to various treatments in colon cancer.
Cat. No. PNAR-1001
Other products
NU-99578
REFRIGERATION Refrigeration System Type Direct cooling Compressor Type/Brand/Number Hermetic Reciprocating...
PCR tube 200 uL transparent flat cap – CP100
200 uL clear single PCR tubes with flat cap. -...
CannaSEX qPCR
Kit for the determination of the sexual dimorphism of Cannabis...
EZ-10 spin column Blood RNA Mini-preps kit(BS82313-50PREPS)
The Miniprep Blood RNA EZ-10 Kit is a simple spin...